KARD (Kardigan) Cash per Share: $3.76 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KARD Kardigan Inc KARD
11 GF Score
Price $20.49
! 1 Warning Sign
View Full Analysis

What is Kardigan Cash per Share?

Kardigan KARD +3.13% 11 Cash per Share is $3.76 as of Dec. 2025. GuruFocus rates KARD with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Kardigan's Cash per Share for the quarter that ended in Dec. 2025 was $3.76.

Kardigan  (NAS:KARD) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Kardigan Cash per Share Related Terms

Kardigan Cash per Share Historical Data

* Premium members only.

The historical data trend for Kardigan's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kardigan Cash per Share Chart

Kardigan Annual Data
Trend Dec24 Dec25
Cash per Share
0.55 3.76

Kardigan Semi-Annual Data
Dec24 Dec25
Cash per Share 0.55 3.76
KARD
11GF Score
Kardigan Inc KARD
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kardigan Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Kardigan's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=335.485/89.34
=3.76

Kardigan's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=335.485/89.34
=3.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $3.76 mean?
Kardigan (KARD) has a Cash per Share of $3.76 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Kardigan and its competitors.
Is Kardigan's Cash per Share too high?
Kardigan's current Cash per Share is $3.76. Overall, Kardigan has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kardigan's Cash per Share compare to OCUL and GHRS?
Kardigan's Cash per Share of $3.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Kardigan and its competitors. Kardigan's current Cash per Share is $3.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kardigan stock overvalued right now?
Kardigan (KARD) has a current Cash per Share of $3.76. The current Cash per Share is $3.76. Kardigan's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Kardigan (KARD), the current Cash per Share is $3.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kardigan Business Description

Address 506 Carnegie Center Drive, Suite 201, Princeton, NJ, USA, 08540
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
11GF Score

Get the complete analysis for KARD

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.49
Price